论文部分内容阅读
早在三十年代,人们已注意到肿瘤患者体内存在着一种对该肿瘤具有特异性的抗原。1965年,Gold和Freedman首先将这种特异性抗原命名为癌胚抗原(Carcinoembryanic antigen,以下简称CEA)。由于当时仅知道CEA在结肠腺癌和其他一些消化系统的恶性肿瘤中存在,故最初认为它是结肠癌和其他内胚层起源肿瘤所特有的一种标记物质。现已知除消化系统恶性肿瘤外,CEA可在人体其他一些部位的恶性肿瘤、特别是肺癌中存在,而且在其诊断和预后上均有着一定的意义。
As early as in the thirties, people have noticed that there is an antigen specific to the tumor in the tumor patient. In 1965, Gold and Freedman first named this specific antigen Carcinoembrylic antigen (CEA). Since only CEA was known to exist in colonic adenocarcinoma and other malignancies of the digestive system, it was initially considered a marker substance specific to colon cancer and other tumors of endoderm origin. It is known that in addition to malignancy of the digestive system, CEA can exist in other parts of the body of malignant tumors, especially lung cancer, and it has a certain significance in its diagnosis and prognosis.